Biosimilars and Biologics

This session of the Biosimilars 2020 will be looking into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilancepractice and pharmacoepidemiology.

• Role of Pharma Industries in the Improvement of Pharmacovigilance System
• Current Problems in Biosimilar Pharmacovigilance
• Detection and Evaluation of Drug Safety Signals
• Pharmacoepidemiology and GMP